Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Google Disrupts Major Residential Proxy Network IPIDEA 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
The Maire - EuroChem Case: Three Lessons for Global Business 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
LONDON, May 23, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Jefferies Healthcare Conference
Date: June 8, 2017
Time: 11:30 AM EDT
Location: New York, NY
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||||
| Aubrey Powell / James White | ||||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||||
| ICR, Inc. (US Media and Investor enquiries) | ||||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
